menu
    • menu
    [{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Neostigmine Methylsulfate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ammonium, (m-hydroxyphenyl)trimethyl-, methyl sulfate, dimethylcarbamate

    Menu

    Ammonium, (m-hydroxyphenyl)trimethyl-, methyl sulfate, dimethylcarbamate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neostigmine Methylsulfate,Glycopyrronium Bromide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches PREVDUO (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approve...

                            Details : PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S for Neuromuscular blockade.

                            Brand Name : Prevduo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Neostigmine Methylsulfate,Glycopyrronium Bromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neostigmine Methylsulfate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Exela Pharma Sciences, LLC.

                            Deal Size : $42.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy

                            Details : Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.

                            Brand Name : Bloxiverz

                            Molecule Type : Small molecule

                            Upfront Cash : $14.5 million

                            July 01, 2020

                            Lead Product(s) : Neostigmine Methylsulfate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Exela Pharma Sciences, LLC.

                            Deal Size : $42.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth